Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Faces Probe On Claims It Derailed Biosimilar Herceptin

Executive Summary

Did Roche engage in abusive market conduct aimed at keeping trastuzumab biosimilar versions at bay in India? The Competition Commission of India has sought a detailed investigation into a string of serious allegations brought about by Biocon and Mylan and has held that some of the Swiss firm’s actions prima facie appear to be aimed at adversely affecting the penetration of biosimilars in the country.

You may also be interested in...



What’s In Store For Roche’s New India Boss?

Lara Bezerra moves from turbulent Venezuela to head Roche in India. Scrip highlights what the incoming Roche boss might expect on the generally peaceful yet complex Indian market.

Biocon Cautiously Optimistic On Earnings Prospects Amid Slower Approvals

India’s biggest biotech firm has said it is “cautiously optimistic” about its performance this financial year after fourth-quarter net profit slid due to an exceptional item in the previous year, but reports progress on multiple fronts for its large biosimilar portfolio.

Biocon Cautiously Optimistic On Earnings Prospects Amid Slower Approvals

India’s biggest biotech firm has said it is “cautiously optimistic” about its performance this financial year after fourth-quarter net profit slid due to an exceptional item in the previous year, but reports progress on multiple fronts for its large biosimilar portfolio.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel